Rebecca E. Parker

Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells

Mohamed Rahmani, Jewel Nkwocha, Elisa Hawkins et al. · Cancer Research · 2018 · 138 citations · Full text

MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity

Alisa B. Lee‐Sherick, Kristen M. Jacobsen, Curtis J. Henry et al. · JCI Insight · 2018 · 71 citations · Full text

Hematological Malignancy, Host Mertk, Cancer Immunosurveillance +14

MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents

Nellie K. McDaniel, Christopher T. Cummings, Mari Iida et al. · Molecular Cancer Therapeutics · 2018 · 63 citations · Full text

MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non–small Cell Lung Cancers Expressing Wild-type <i>EGFR</i> Family Members

Dan Yan, Rebecca E. Parker, Xiaodong Wang et al. · Clinical Cancer Research · 2018 · 32 citations

Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation

Mohamed Rahmani, Mandy Mayo Aust, Edith P. Hawkins et al. · Haematologica · 2015 · 31 citations · Full text